Business Description
GT Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US6918295014
Total Employee Number:
1Description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.76 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 35.9 | |||||
3-Year EPS without NRI Growth Rate | 55.8 | |||||
3-Year FCF Growth Rate | 45.1 | |||||
3-Year Book Growth Rate | -72.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 66.32 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.14 | |||||
Quick Ratio | 4.14 | |||||
Cash Ratio | 3.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -186 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -752.6 | |||||
ROA % | -472.15 | |||||
ROIC % | -6013.53 | |||||
3-Year ROIIC % | -3025.68 | |||||
ROC (Joel Greenblatt) % | -6157.84 | |||||
ROCE % | -719.29 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 6.05 | |||||
PEG Ratio | 0.22 | |||||
PB Ratio | 2.19 | |||||
Price-to-Tangible-Book | 2.15 | |||||
EV-to-EBIT | -0.28 | |||||
EV-to-EBITDA | -0.28 | |||||
EV-to-FCF | -0.61 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.24 | |||||
Price-to-Graham-Number | 0.77 | |||||
| Price-to-Net-Current-Asset-Value | 2.15 | |||||
| Price-to-Net-Cash | 2.62 | |||||
Earnings Yield (Greenblatt) % | -357.14 | |||||
FCF Yield % | -77.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
GT Biopharma Inc Executives
DetailsGF Valueā¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ā¬) | |||
| EPS (TTM) (ā¬) | -8.928 | ||
| Beta | 0.113 | ||
| 3-Year Sharpe Ratio | -0.58 | ||
| 3-Year Sortino Ratio | -0.73 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (ā¬) | - | ||
| 20-Day SMA (ā¬) | 4.77 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (ā¬) | 4.77 - 4.77 | ||
| Shares Outstanding (Mil) | 36.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GT Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GT Biopharma Inc Stock Events
| Event | Date | Price (ā¬) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 132 days | ||
| General meeting for 2026 | 2026-08-14 11:00 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 41 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 4.77 (+0.00%) | ||
| CENTURION ONE CAPITAL 9TH ANNUAL TORONTO GROWTH CONFERENCE | 2026-03-05 08:00 | 4.77 (+0.00%) | ||
| Annual report for 2025 | 2026-03-02 | 4.77 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-02 | 4.77 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 4.77 (+0.00%) | ||
| H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE | 2025-09-09 10:30 | 4.77 (+0.00%) | ||
| H.C. Wainwright Conference September | 2025-09-05 07:00 | 4.77 (+0.00%) |
Show
Entries
GT Biopharma Inc Frequently Asked Questions
What is GT Biopharma Inc(FRA:OXIA)'s stock price today?
The current price of FRA:OXIA is ā¬4.77. The 52 week high of FRA:OXIA is ā¬4.77 and 52 week low is ā¬4.77.
When is next earnings date of GT Biopharma Inc(FRA:OXIA)?
The next earnings date of GT Biopharma Inc(FRA:OXIA) is 2026-08-14 Est..
Does GT Biopharma Inc(FRA:OXIA) pay dividends? If so, how much?
GT Biopharma Inc(FRA:OXIA) does not pay dividend.
Press Release
Articles on GT Biopharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers